Comprehensive Metabolic Panel Market is segmented By Disease (Kidney Diseases, Diabetes, Liver Diseases, Others), By End-User (Point-of-care Centers, Laboratories, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.
The Comprehensive Metabolic panel market size was valued at US$ million in 2020 and is estimated to reach US$ million by 2028, growing at a CAGR of 7.1% during the forecast period (2022-2029).
The comprehensive metabolic panel, also known as the chemical screen, consists of 14 blood tests used as an initial broad medical screening tool.
Comprehensive Metabolic Panel Market Scope
|
Metrics |
Details |
|
Market CAGR |
7.1% |
|
Segments Covered |
By Disease, By End-User, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
Market Dynamics
The factors driving the market are the rising awareness among people about the diagnosis of disease and advancements in point of care diagnostics in people.
Rising awareness among people about the diagnosis of the disease is expected to drive the market growth
Clinical laboratory tests have an incalculable impact on health care providers' diagnostic and treatment decisions. At a time when evidence-based laboratory medicine (EBLM) is becoming more popular among health care professionals, the information provided by clinical lab tests aids in the accurate and timely diagnosis, treatment, and monitoring of patients. The comprehensive metabolic panel (CMP) is a broad screening tool used to assess the health of organs and screen for conditions like diabetes, liver disease, and kidney disease.
Disease and symptom awareness are critical for screening and early detection. When the general public is aware of a disease and its symptoms, they are more likely to take precautions to avoid contracting it or to visit a healthcare provider for a check-up. The majority of people receive a CMP as part of their yearly check-up. The doctor may also want one to check for problems, monitor any chronic conditions have, or ensure that certain medications aren't harming the liver or kidneys. A comprehensive metabolic panel (CMP-14) consists of 14 different blood tests that provide information on one's body's levels of glucose, calcium, proteins, electrolytes, and lipid panel, as well as liver and kidney function. Hence, rising awareness among people about disease diagnosis is expected to drive the market. Health care providers' diagnostic and treatment decisions. At a time when evidence-based laboratory medicine (EBLM) is becoming more popular among health care professionals, the information provided by clinical lab tests aids in the accurate and timely diagnosis, treatment, and monitoring of patients. The comprehensive metabolic panel (CMP) is a broad screening tool used to assess the health of organs and screen for conditions like diabetes, liver disease, and kidney disease.
Disease and symptom awareness are critical for screening and early detection. When the general public is aware of a disease and its symptoms, they are more likely to take precautions to avoid contracting it or to visit a healthcare provider for a check-up. The majority of people receive a CMP as part of their yearly check-up. The doctor may also want one to check for problems, monitor any chronic conditions have, or ensure that certain medications aren't harming the liver or kidneys. A comprehensive metabolic panel (CMP-14) consists of 14 different blood tests that provide information on one's body's levels of glucose, calcium, proteins, electrolytes, and lipid panel, as well as liver and kidney function. Hence, rising awareness among people about disease diagnosis is expected to drive the market.
Limitations of the comprehensive metabolic panel are expected to hamper the market growth
The doctor will examine all the results together to look for patterns. The combination of patterns can indicate that one may have liver or kidney disease. If a patient is in the hospital, the doctor may perform daily tests. If they aren't, but the patient has a disease such as diabetes or kidney disease, then they may need to visit their doctor's office or a clinic every few months for tests. Many factors affect the testing procedure medications one may be taking, such as steroids, insulin, or hormones, having something to eat or drink before the test, exercising before the exam and damage to blood cells during collection or processing for a blood test. A CMP (Comprehensive Metabolic Panel) costs between $10 and $132. MP tests may be provided for free as part of a health insurance plan's preventive care coverage, which is frequently provided at no cost. But only one test per year may be fully covered, but additional tests may be covered only partially or not at all.
Industry Analysis
COVID-19 Impact Analysis
COVID-19 has affected the healthcare industry moderately. To stop its spread, government-imposed lockdown. People are fearful they may experience occupational effects and negative health from the COVID-19 pandemic. This restricted most of the diagnostic tests. With the increase in COVID-19, there has been an increase in blood testing, and this increase in testing has stimulated the demand for a comprehensive metabolic panel market. This has affected the global comprehensive metabolic panel market partially.
Segment Analysis
The kidney disease segment held the largest share in the comprehensive metabolic panel market
The rising prevalence of kidney diseases, early diagnosis, and increasing disease incidence over the period due to factors such as sedentary lifestyles, changing food habits, and an increase in diabetic patients worldwide is expected to dominate the market. In 2017, there were 697.5 million cases of CKD (all stages) recorded worldwide, representing a global prevalence of 9.1 per cent. Chronic kidney disease (CKD) affects 10% of the global population, and millions die each year as a result of a lack of affordable treatment. The CMP tests two waste products produced by your kidneys: blood urea nitrogen (BUN) and creatinine. Normal ranges are BUN (blood urea nitrogen): 6-20 mg/dL and Creatinine: 0.6-1.3 mg/dL.
The Piccolo Comprehensive Metabolic Panel is designed to be used in conjunction with the Piccolo blood chemistry analyzer or the Piccolo Xpress chemistry analyzer for the in vitro quantitative determination of alanine aminotransferase (ALT), albumin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), calcium, chloride, creatinine, glucose, potassium, sodium, total bilirubin, total carbon dioxide, total (BUN).
Geographical Analysis
North America region accounted for the largest market share in the global comprehensive metabolic panel market
This region is projected to grow at a high CAGR during the forecast period due to rising disease incidence and the presence of major key players. Chronic kidney disease is a major health problem in the North American region. More than one in seven, or 15% of US adults, or 37 million people, is estimated to have CKD. As many as 9 out of 10 adults with CKD are unaware of their condition. Approximately one-half of all adults with severe CKD are unaware of their condition. According to CDC, in 2019, the number of American adults with chronic kidney disease (CKD) is now estimated to be 37 million, one out of every seven or 15% of the adult population (CDC).
Diabetes has been discovered to broaden the patient pool for point-of-care (POC) CMP testing. Diabetes and high blood pressure have been identified as the leading causes of CKD in adults. Other diabetes risk factors include heart disease, obesity, a family history of CKD, kidney damage in the past, and advanced age. Furthermore, favorable reimbursement policies and government support are expected to aid market growth.
Competitive Landscape
The global comprehensive metabolic panel market is highly competitive with rising disease incidence, advancement in diagnostic procedures, product launches and mergers. Some of the major key players in the global comprehensive metabolic panel market are Weldonbiotech, McKesson Medical-Surgical, Abaxis, Beckman Coulter, UNIPATH, Nova Biomedical, Werfen among others
Nova Biomedical
Overview: Nova Biomedical designs, manufacture and sells high-tech blood testing analyzers. We employ over 1,400 people and have sales and service subsidiaries in eight countries as well as distributors in an additional 91 countries. Nova has manufacturing facilities in Waltham, Billerica, and Taipei, Massachusetts, as well as Taipei, Taiwan. Nova is one of the world's top 25 in vitro diagnostic companies and the largest privately held in vitro diagnostic company in the United States.
Product Portfolio: Nova manufactures a line of automated cell culture analyzers called BioProfile® that allow for the rapid analysis of key nutrients, metabolites, pH, gases, and cell density/cell viability. company based in the United States. Some of their products are Stat Profile Prime Plus Critical Care Analyzer, pHOx Ultra, Stat Profile Prime Plus and Stat Profile Prime.
Key Development: On April 15th, 2020, Nova Biomedical’s Stat Profile Prime Plus critical care blood gas analyzer had been cleared for point-of-care (POC) use by the US Food and Drug Administration (FDA). POC personnel can now perform bedside critical care testing with lab-quality results in as little as one minute with this clearance. Prime Plus uses maintenance-free sensor technology to perform 19 essential critical care tests such as blood gases, electrolytes, metabolites, hematology, and co-oximetry, providing clinicians with a rapid, detailed diagnostic profile that includes a comprehensive metabolic panel.
Frequently Asked Questions
What is the Projected CAGR value of the Comprehensive Metabolic Panel Market?
Comprehensive Metabolic Panel Market is expected to grow at a CAGR of 7.1% during the forecasting period 2022-2029.
Which region controlled the global market during 2022-2029?
North America region Controls the Comprehensive Metabolic Panel Market during 2022-2029.
Which is the fastest growing region in the Comprehensive Metabolic Panel Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period.
Trending Topics
Preimplantation Genetic Diagnosis Market
Molecular Biology Enzymes And Kits & Reagents Diagnosis Market
